Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 3 of 3 results for eflornithine

  1. Eflornithine for treating high-risk neuroblastoma with complete or partial response after immunotherapy [ID4060]

    In development [GID-TA10990] Expected publication date: 25 June 2025

    Technology appraisal guidance
    In development

  2. Eflornithine with sulindac for treating familial adenomatous polyposis [ID1543]

    Discontinued [GID-TA10536]

    Technology appraisal guidance
    Discontinued

  3. Eflornithine with lomustine for treating anaplastic astrocytoma after radiotherapy and adjuvant temozolomide TS ID 10046

    Awaiting development [GID-TA11335] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development